These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38069368)

  • 21. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells.
    Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y
    Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress.
    Ma P; Han W; Meng C; Tan X; Liu P; Dong L
    Anal Cell Pathol (Amst); 2022; 2022():6100176. PubMed ID: 36311891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced expression of lncRNA ZXF1 promotes cisplatin resistance in lung cancer cell via MAPK axis.
    Yu T; Bai W; Su Y; Wang Y; Wang M; Ling C
    Exp Mol Pathol; 2020 Oct; 116():104484. PubMed ID: 32533982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2/NAMPT axis.
    Chen H; Wang L; Liu J; Wan Z; Zhou L; Liao H; Wan R
    Cancer Biol Ther; 2023 Dec; 24(1):2223377. PubMed ID: 37370246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway.
    Lu T; Lu W; Jia C; Lou S; Zhang Y
    Adv Clin Exp Med; 2021 Aug; 30(8):849-857. PubMed ID: 34286518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
    Cui Z; Li D; Zhao J; Chen K
    Free Radic Biol Med; 2022 Apr; 183():106-124. PubMed ID: 35278641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
    Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
    Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
    Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
    Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors.
    Pandey N; Tyagi G; Kaur P; Pradhan S; Rajam MV; Srivastava T
    Cell Physiol Biochem; 2020 Aug; 54(4):748-766. PubMed ID: 32809300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
    Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
    Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
    BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
    Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.
    Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.